CHANDLER, Ariz.--(BUSINESS WIRE)--InNexus Biotechnology Inc. (TSX:IXS.V), a biopharmaceutical company creating and developing innovative solutions for cancer, inflammation and other difficult-to-treat diseases, announces that it has, effective August 26, 2011, granted incentive stock options to purchase an aggregate of 1,068,683 common shares without par value in the capital of the Company to certain persons who are either a director, officer, employee or consultant of the Company. The stock options will be exercisable for a period 5 years expiring on August 27, 2016 at a price of $0.05 per common share.
